Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m 2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m 2
Journal article published in 2019 by
Kevin Barley,
Larysa Sanchez 
,
Hearn J. Cho,
Samir Parekh,
Deepu Madduri,
Joshua Richter,
Luis Isola,
Talia Goldstein,
Amishi Dhadwal,
Katarzyna Zarychta,
Gillian Morgan Sanchez,
Donna Catamero,
Daniel Verina,
Erika Florendo,
Moon‐hee Yum
and other authors.
,
Hearn J. Cho,
Samir Parekh,
Deepu Madduri,
Joshua Richter,
Luis Isola,
Talia Goldstein,
Amishi Dhadwal,
Katarzyna Zarychta,
Gillian Morgan Sanchez,
Donna Catamero,
Daniel Verina,
Erika Florendo,
Moon‐hee Yum
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 